Drug intelligence / Profile preview

diampromide

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Intramuscular
01

Overview

Diampromide is a synthetic opioid analgesic of the ampromide family, structurally related to propiram and phenampromide, and can be described as a ring-opened analogue of fentanyl. It was invented in the 1960s by American Cyanamid. Pharmacologically, it acts as an opioid agonist with effects similar to morphine, including analgesia, sedation, dizziness, and nausea. Its potency is approximately equivalent to morphine in animal models. It has been evaluated for postoperative pain but is not approved or marketed for medical use in any country. Diampromide is classified as a Schedule I controlled substance under the United States Controlled Substances Act and under international conventions due to its high potential for abuse and lack of accepted medical use[1][4][10].

Other names
diampromideDiampromidDiampromidum [INN-Latin]N-(2-(methylphenethylamino)propyl)propionanilide
02

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on diampromide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diampromide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call